|
Canada-0-CLOTHING 公司名錄
|
公司新聞:
- Investors | Endo - Press Releases
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader - Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs - Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun Off as an Independent Company with Target Date in the Fourth Quarter of
- Endo - Home | Introducing Keenova and Par Health
On July 31, 2025, Mallinckrodt and Endo joined together to better serve patients and customers with a bold plan for the future Following the merger, the combined company then spun off its generics and sterile injectables business as an independent company—Par Health—and rebranded the specialty therapeutics company as Keenova Therapeutics in November 2025
- Mallinckrodt and Endo to Combine to Create a Global, Scaled . . .
About Endo Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies Our passionate team members collaborate to develop and deliver these essential medicines Together, we are committed to helping everyone we serve live their best life Learn more at www endo com or connect with us on LinkedIn
- Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May 12, 2025
- Investors | Endo - Overview
Endo’s board of directors oversees and advises our leaders to protect the long-term interests of the company and our shareholders The experienced and independent board members are committed to building sustainable success
- Endo, Inc. Completes Acquisition of Endo International plcs Assets
MALVERN, Pa , April 23, 2024 PRNewswire -- Endo, Inc ("Endo" or the "Company"), a newly formed entity, today announced that it has successfully completed the previously announced acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization (the "Plan")
- Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results
Endo achieved 2024 revenues and adjusted EBITDA expectations, while progressing the Company's strategic priorities XIAFLEX® hit record revenues of $516 million in 2024, up 9% versus 2023 The Company provides 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million MALVERN, Pa , March 13, 2025 PRNewswire -- Endo, Inc ("Endo" or the "Company
- Endo Receives U. S. FDA Approval of Manufacturing Facility in Indore . . .
20,000-square-foot site increases Endo's sterile injectable production capacity This marks the site's first U S FDA approval Endo is investing and innovating in its Injectable Solutions business MALVERN, Pa , Dec 9, 2024 PRNewswire -- Endo, Inc (OTCQX: NDOI) announced today that the U S Food and Drug Administration (FDA) has approved commercial production of VASOSTRICT ® (vasopressin
- Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into a new standalone entity separate from the remaining branded pharmaceuticals business
- Investors | Endo - Press Releases
Endo Announces Peyronie's Disease Presentation at the North Central Section of the American Urological Association Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that a presentation related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH,
|
|